As of 2025-06-14, the Intrinsic Value of Nectar Life sciences Ltd (NECLIFE.NS) is 20.25 INR. This NECLIFE.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 23.99 INR, the upside of Nectar Life sciences Ltd is -15.60%.
The range of the Intrinsic Value is 13.23 - 30.84 INR
Based on its market price of 23.99 INR and our intrinsic valuation, Nectar Life sciences Ltd (NECLIFE.NS) is overvalued by 15.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 13.23 - 30.84 | 20.25 | -15.6% |
| DCF (Growth 10y) | 17.42 - 34.19 | 24.23 | 1.0% |
| DCF (EBITDA 5y) | 45.69 - 88.47 | 67.77 | 182.5% |
| DCF (EBITDA 10y) | 35.24 - 71.74 | 52.55 | 119.0% |
| Fair Value | 3.79 - 3.79 | 3.79 | -84.20% |
| P/E | 20.70 - 34.62 | 27.46 | 14.5% |
| EV/EBITDA | 34.71 - 95.87 | 60.66 | 152.8% |
| EPV | (0.07) - 7.32 | 3.63 | -84.9% |
| DDM - Stable | 1.93 - 3.62 | 2.77 | -88.4% |
| DDM - Multi | 8.75 - 13.44 | 10.64 | -55.6% |
| Market Cap (mil) | 5,380.00 |
| Beta | 0.48 |
| Outstanding shares (mil) | 224.26 |
| Enterprise Value (mil) | 11,488.76 |
| Market risk premium | 8.31% |
| Cost of Equity | 25.20% |
| Cost of Debt | 13.18% |
| WACC | 16.66% |